Kevin McCulloch, the President and Chief Operating Officer of Xeris Biopharma Holdings, Inc., has sold 15,000 shares of the company’s common stock. This transaction, which occurred on November 2, 2026, is part of a pre-established trading plan.

This sale is significant as it underscores the ongoing trading activities of executives in the pharmaceutical preparations sector. Xeris Biopharma, which focuses on innovative drug delivery systems, continues to operate in a competitive industry.

Background

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company based in Chicago, Illinois. The company specializes in pharmaceutical preparations, classified under Standard Industrial Classification 2834. Xeris is publicly traded on the stock exchange with the ticker symbol XERS.

What the Filing Says

According to the SEC filing dated November 4, 2026, McCulloch's transaction was executed under a Rule 10b5-1 trading plan adopted on September 4, 2025. The shares were sold at a weighted average price of $10.2325, with prices ranging from $10.110 to $10.490.

Impact

This transaction may influence shareholders and investors as it reflects the financial decisions of the company's top executives. McCulloch's sale leaves him with 1,584,208 shares owned following the transaction, while his spouse holds an additional 25,000 shares.

What's Next

The filing does not say what happens next.